Document is current

Article History

Accepted: 14 January 2021

First Online: 25 February 2021

Competing interests

: M.A.P. has acted as an advisor for Mesoblast and Novartis, has received research funding from Adaptive and Miltenyi, and has received honoraria for educational activities from Miltenyi and Novartis. N.A. has acted as a consultant for Adaptimmune and continues to consult for Equillium (pro bono) and The Children’s Cancer Hospital Egypt 57357 on medical education and research development, has received one-time royalties from Celgene and Cell Medica, and is a named inventor on patents and patent applications in the field of chimeric antigen receptor (CAR) T cell therapy owned by Baylor College of Medicine. M. Hamieh is listed on patents relating to CAR technologies and has received royalties from Atara Biotherapeutics, Fate Therapeutics and Takeda Pharmaceuticals. M. Hegde is a named inventor on patents and patent applications in the field of CAR T cell therapy owned by Baylor College of Medicine. M.R. has acted as a consultant of AbClon, Bristol-Myers Squibb (BMS), Mesoblast, NanoString, and Novartis, has received research support from Adaptive and Miltenyi, and is listed on patents relating to CAR technologies and receives royalties from Novartis and Tmunity. B.S. has acted as a consultant of Tessa Therapeutics, has received research funding from Bellicum Pharmaceuticals, Bluebird Bio, Cell Medica and Tessa Therapeutics, and is listed on patents in the field of CAR and T cell receptor (TCR) therapy. C.J.T. has served on the scientific advisory boards of ArsenalBio, Caribou Biosciences, Century Therapeutics, Eureka Therapeutics, Myeloid Therapeutics, Precision Biosciences and T-CURX, has acted as an ad hoc consultant of Allogene, Amgen, AstraZeneca, Nektar Therapeutics and PACT Pharma, has stock/options in ArsenalBio, Caribou Biosciences, Eureka Therapeutics, Myeloid Therapeutics and Precision Biosciences, has received research funding from AstraZeneca, Juno Therapeutics/BMS, Minerva, Nektar Therapeutics and TCR2 Therapeutics, and is listed on a patent licensed to Juno Therapeutics. A.S.W. has received research support from Kite Pharma and Institut de Recherches Internationales Servier. E.F., D.L.W., N.N.S. and M.A. declare no competing interests.